Premium
Review article: unanswered clinical and research questions in autoimmune hepatitis‐conclusions of the International Autoimmune Hepatitis Group Research Workshop
Author(s) -
Dyson Jessica K.,
De Martin Eleonora,
Dalekos George N.,
Drenth Joost P.H.,
Herkel Johannes,
Hubscher Stefan G.,
Kelly Deirdre,
Lenzi Marco,
Milkiewicz Piotr,
Oo Ye H.,
Heneghan Michael A.,
Lohse Ansgar W.
Publication year - 2019
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15111
Subject(s) - autoimmune hepatitis , medicine , disease , liver disease , hepatitis , autoantibody , intensive care medicine , immunology , antibody
SUMMARY Background Autoimmune hepatitis ( AIH ) is a chronic inflammatory liver disease that results in substantial morbidity and mortality with many unanswered clinical and research questions. Improved understanding of disease pathogenesis, including the extra‐hepatic manifestations of AIH, may allow targeted treatments with greater efficacy and fewer associated adverse events. Aim To identify the spectrum of unanswered clinical and research questions facing care providers in the management of patients with autoimmune hepatitis ( AIH ). Methods The International Autoimmune Hepatitis Group initiated a series of research workshops to start to address these questions. Key issues were discussed in small group sessions with collation of all discussions to be summarised in this manuscript. Results Key issues were identified as: the need for better understanding of disease pathogenesis, standardisation of the methods and assays used to evaluate autoantibodies in AIH, refinement of the histopathological criteria for “typical” or “compatible” AIH, focus on the interaction with non‐alcohol related fatty liver disease, how to treat acute severe AIH, better assessment of quality of life in adults and paediatrics, standardising use of standard, third‐line and experimental therapies in AIH and search for biomarkers early in the disease course that predict outcome. Conclusion This workshop has outlined the key unanswered clinical and research questions to help to define the research agenda in AIH.